Document
IPR2017-01910, No. 1103-103 Exhibit - Ogasawara, Effects of Experimental Chemoendocrine Therapy with a Combination of a Pure Antiestrogen and 5 Fluorouracil on Human Breast Cancer Ce...
Cite Document
IPR2017-01910, No. 1103-103 Exhibit - Ogasawara, Effects of Experimental Chemoendocrine Therapy with a Combination of a Pure Antiestrogen and 5 Fluorouracil on Human Breast Cancer Cells Implanted in N
+ More Snippets
Document
IPR2017-01910, No. 1106-106 Exhibit - Remingtons Pharmaceutical Sciences 1538 39, 1545 50, 1686 88 18th ed 1990 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1106-106 Exhibit - Remingtons Pharmaceutical Sciences 1538 39, 1545 50, 1686 88 18th ed 1990 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1075-75 Exhibit - Robertson, JFR et al, A Partially Blind, Randomised, Multicentre Study Comparing the Anti Tumor Effects of Single Doses 50, 125, 250 mg Of Long Acting F...
Cite Document
IPR2017-01910, No. 1075-75 Exhibit - Robertson, JFR et al, A Partially Blind, Randomised, Multicentre Study Comparing the Anti Tumor Effects of Single Doses 50, 125, 250 mg Of Long Acting Faslodex ICI
+ More Snippets
Document
IPR2017-01910, No. 1102-102 Exhibit - Nema, Excipients and Their Use in Injectable Products, 51 PDA J PHARM SCI TECH 166 71 1997 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1102-102 Exhibit - Nema, Excipients and Their Use in Injectable Products, 51 PDA J PHARM SCI TECH 166 71 1997 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1010-10 Exhibit - Order, AstraZeneca Pharms LP v Sandoz Inc, No 14 03547 DNJ July 29, 2015, ECF No 102 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1010-10 Exhibit - Order, AstraZeneca Pharms LP v Sandoz Inc, No 14 03547 DNJ July 29, 2015, ECF No 102 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1007-7 Exhibit - Howell et al, Pharmacokinetics, pharmacological and anti tumour effects of the specific anti oestrogen ICI 182780 in women with advanced breast cancer, 74...
Cite Document
IPR2017-01910, No. 1007-7 Exhibit - Howell et al, Pharmacokinetics, pharmacological and anti tumour effects of the specific anti oestrogen ICI 182780 in women with advanced breast cancer, 74 BRIT J CA
+ More Snippets
Document
IPR2017-01910, No. 1005-5 Exhibit - Reserved (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1005-5 Exhibit - Reserved (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1078-78 Exhibit - Petition for Inter Partes Review in Mylan Pharms Inc v AstraZeneca AB, Paper No 2, IPR2016 01316 PTAB June 29, 2016 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1078-78 Exhibit - Petition for Inter Partes Review in Mylan Pharms Inc v AstraZeneca AB, Paper No 2, IPR2016 01316 PTAB June 29, 2016 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1016-16 Exhibit - US Patent No 4,659,516 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1016-16 Exhibit - US Patent No 4,659,516 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1060-60 Exhibit - Howell, Fulvestrant Revisited Efficacy and Safety of the 500 mg Dose, 11 CLINICAL BREAST CANCER 204 10 2011 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1060-60 Exhibit - Howell, Fulvestrant Revisited Efficacy and Safety of the 500 mg Dose, 11 CLINICAL BREAST CANCER 204 10 2011 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1056-56 Exhibit - Howell, Response to a Specific Antioestrogen ICI 182780 in Tamoxifen Resistant Breast Cancer, 345 LANCET 29 30 1995 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1056-56 Exhibit - Howell, Response to a Specific Antioestrogen ICI 182780 in Tamoxifen Resistant Breast Cancer, 345 LANCET 29 30 1995 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1031-31 Exhibit - Wakeling et al, A Potent Specific Pure Antiestrogen with Clinical Potential, 51 CANCER RESEARCH 3867 3873 1991 (P.T.A.B. Aug. 4, 2017)
Cite Document
IPR2017-01910, No. 1031-31 Exhibit - Wakeling et al, A Potent Specific Pure Antiestrogen with Clinical Potential, 51 CANCER RESEARCH 3867 3873 1991 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1062-62 Exhibit - Freireich, Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man, 50 CANCER CHEMOTHERAPY REPO...
Cite Document
IPR2017-01910, No. 1062-62 Exhibit - Freireich, Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man, 50 CANCER CHEMOTHERAPY REPORTS 219 44 1966 (P.T.A
+ More Snippets
Document
IPR2017-01910, No. 1038-38 Exhibit - DeFriend et al, Investigation of a New Pure Antiestrogen ICI 182780 in Women with Primary Breast Cancer, 54 CANCER RESEARCH 408 414 1994 (P.T.A...
Cite Document
IPR2017-01910, No. 1038-38 Exhibit - DeFriend et al, Investigation of a New Pure Antiestrogen ICI 182780 in Women with Primary Breast Cancer, 54 CANCER RESEARCH 408 414 1994 (P.T.A.B. Aug. 4, 2017)
+ More Snippets
Document
IPR2017-01910, No. 1057-57 Exhibit - Dukes, Antiuterotrophic Effects of the Pure Antioestrogen ICI 182,780 in Adult Female Monkeys Macaca nemestrina Quantitative Magnetic Resonance Ima...
Cite Document
IPR2017-01910, No. 1057-57 Exhibit - Dukes, Antiuterotrophic Effects of the Pure Antioestrogen ICI 182,780 in Adult Female Monkeys Macaca nemestrina Quantitative Magnetic Resonance Imaging, 138 J ENDO
+ More Snippets